AI-generated analysis. Always verify with the original filing.
Aura Biosciences reported Q4 and FY 2025 financial results, highlighting accelerated Phase 3 enrollment with topline data expected in 2H 2027 and a cash runway extending into Q1 2027.
Event Type
Disclosure
Mandatory
Variant
8-K
, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
or in the materials filed herewith in the event of new information, future developments or otherwise. These forward-looking statements are based on the Company’
Financial Statements and Exhibits. (d) Exhibits. | Exhibit No . | Description | |---|---| | 99.1 | Press Release Dated March 30, 2026. | | 99.2 | Corporate Pres
| Metric | Value | Basis |
|---|---|---|
| Research and Development Expenses | $21.90 | GAAP |
| Research and Development Expenses | $90.30 | GAAP |
| General and Administrative Expenses | $5.30 | GAAP |
| General and Administrative Expenses | $22.50 | GAAP |
| Net Loss | $25.60 | GAAP |
| Net Loss | $106.20 | GAAP |
| Net Loss Per Common Share | $1.76 | GAAP |
Cash Runway
—
Phase 3 CoMpass Enrollment Completion
—
Phase 3 CoMpass Topline Data
—
Phase 1b/2 NMIBC Initial Data
—